Mustang Bio, Inc.
MBIO
$0.61
-$0.02-3.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 542.60% | -31.64% | -48.60% | -14.72% | -110.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2,676.92% | -57.17% | -84.98% | -95.16% | -100.29% |
| Operating Income | -2,676.92% | 57.17% | 84.98% | 95.16% | 100.29% |
| Income Before Tax | 43.49% | 66.81% | 90.71% | 97.05% | 88.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.49% | 66.81% | 90.71% | 97.05% | 88.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.49% | 66.81% | 90.71% | 97.05% | 88.95% |
| EBIT | -2,676.92% | 57.17% | 84.98% | 95.16% | 100.29% |
| EBITDA | -970.13% | 55.62% | 84.22% | 95.57% | 100.90% |
| EPS Basic | 90.75% | 96.17% | 98.97% | 99.78% | 97.91% |
| Normalized Basic EPS | -196.83% | 96.16% | 98.48% | 99.78% | 100.19% |
| EPS Diluted | 90.75% | 96.17% | 98.97% | 99.78% | 97.91% |
| Normalized Diluted EPS | -196.83% | 96.16% | 98.48% | 99.78% | 100.19% |
| Average Basic Shares Outstanding | 510.99% | 765.82% | 800.43% | 1,267.54% | 428.81% |
| Average Diluted Shares Outstanding | 510.99% | 765.82% | 800.43% | 1,267.54% | 428.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |